SEC Form 4 · accession 0001140361-17-000853
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Paul J Hastings
Officer — Chairman & CEO · Director
Period of report
Jan 3, 2017
Accepted (ET)
Jan 5, 2017 · 7:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $7.66 | Jan 3, 2017 | A | 176,000 | A | — | Jan 2, 2027 | Common Stock | 176,000 | 176,000 | D |
Explanation of responses
- F1The option vests with respect to 1/48 of the shares subject thereto on each monthly anniversary of the date of grant, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.